Q-omics provides the consensus-scored HDGF profile across patient tissues and cancer cell-line models. HDGF expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, HDGF is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, HDGF protein abundance shows 20,953 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, BLCA, and GBM as cancer lineages where HDGF shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HDGF — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HDGF survival associations across molecular data types. HDGF RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HDGF RNA expression–survival associations across cancer types. High HDGF expression shows unfavorable associations in KIRP, ACC, LIHC, MESO, CESC and UCEC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for HDGF RNA expression.
This table summarizes HDGF tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for HDGF. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HDGF shows higher tumor expression in BLCA, HNSC, KIRC, LUAD, STAD and LIHC. The BLCA box plot shows higher HDGF RNA expression in tumor versus normal tissue (log2 FC = +1.461, t-test p < 0.001).
This table shows molecular features associated with HDGF in patient tissues and cancer cell lines. In patient samples, HDGF shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HDGF RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
